Satellos Bioscience Inc. (MSCL.TO)
CAD 0.89
(-4.3%)
CAD 0.89
(-4.3%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Operating Cash Flow | -14.5 Million | -5.78 Million | -5.03 Million | -1.65 Million | -1.92 Million |
| Net Income | -15.88 Million | -11.32 Million | -15.5 Million | -1.57 Million | -1.98 Million |
| Depreciation & Amortization | 7000.00 | 337 Thousand | 165.68 Thousand | 422.00 | 734.00 |
| Deferred income taxes | - | - | - | - | - |
| Stock-based compensation | 2.16 Million | 1.44 Million | 971.53 Thousand | 88.6 Thousand | 37.44 Thousand |
| Change in working capital | 369 Thousand | 991 Thousand | -485.63 Thousand | -182.92 Thousand | -454.03 Thousand |
| Other non-cash items | -363 Thousand | -140 Thousand | 9.84 Million | 5470.00 | 479.86 Thousand |
| Investing Cash Flow | -17.53 Million | -3000.00 | 1.73 Million | - | -771.00 |
| Investments in PPE | -18 Thousand | -3000.00 | -7246.00 | - | -771.00 |
| Acquisitions | - | - | 1.74 Million | - | - |
| Investment purchases | -17.52 Million | - | - | - | - |
| Sales/Maturities of investments | - | - | - | - | - |
| Other Investing Activities | -17.52 Million | - | 1.74 Million | - | - |
| Financing Cash Flow | 51.03 Million | 2.77 Million | 7.45 Million | 1.97 Million | 1.15 Million |
| Debt repayment | -284 Thousand | - | -186.57 Thousand | -1.08 Million | - |
| Dividends payments | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - |
| Common Stock Issuance | 32.46 Million | 2.77 Million | 7.07 Million | 890.54 Thousand | - |
| Other Financing Activities | 603 Thousand | 2.77 Million | 7.26 Million | 890.54 Thousand | 1.15 Million |
| Accounts receivables | -323 Thousand | 1783.00 | 40.12 Thousand | -29.4 Thousand | -12.5 Thousand |
| Accounts payables | - | - | - | - | - |
| Inventory | - | - | - | - | - |
| Other working capital | -425 Thousand | 265 Thousand | -135.29 Thousand | 291.33 Thousand | -441.53 Thousand |
| Cash at beginning of period | 1.92 Million | 4.87 Million | 717.53 Thousand | 399.12 Thousand | 1.16 Million |
| Cash at end of period | 22.06 Million | 1.92 Million | 4.87 Million | 717.53 Thousand | 399.12 Thousand |
| Capital Expenditure | -18 Thousand | -3000.00 | -7246.00 | - | -771.00 |
| Effect of forex changes on cash | 1.14 Million | -76 Thousand | -1444.00 | - | - |
| Net cash flow / Change in cash | 20.14 Million | -2.94 Million | 4.15 Million | 318.4 Thousand | -767.94 Thousand |
| Free Cash Flow | -14.51 Million | -5.78 Million | -5.04 Million | -1.65 Million | -1.92 Million |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 FY | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | -6.03 Million | -6.9 Million | -6.53 Million | -15.88 Million | -3.57 Million | -4.11 Million |
| Depreciation & Amortization | 3000.00 | 2000.00 | 2000.00 | 7000.00 | 2687.00 | 1313.00 |
| Deferred income taxes | - | - | - | - | - | - |
| Stock-based compensation | 693 Thousand | 736 Thousand | 854 Thousand | 2.16 Million | 744.69 Thousand | 369.3 Thousand |
| Change in working capital | -134 Thousand | -253 Thousand | 1.05 Million | 369 Thousand | 415.43 Thousand | -1.37 Million |
| Other non-cash items | 784 Thousand | -587 Thousand | 545 Thousand | -363 Thousand | -1.11 Million | 48.51 Thousand |
| Investing Cash Flow | 2.35 Million | -2.1 Million | -17.52 Million | -17.53 Million | -10.13 Thousand | -6867.00 |
| Investments in PPE | -4000.00 | -2000.00 | -1000.00 | -18 Thousand | -10.13 Thousand | -6867.00 |
| Acquisitions | - | - | - | - | - | - |
| Investment purchases | 2.09 Million | -2.09 Million | - | -17.52 Million | - | - |
| Sales/Maturities of investments | 259 Thousand | - | - | - | - | - |
| Other Investing Activities | 2.35 Million | -2.09 Million | -17.52 Million | -17.52 Million | - | - |
| Financing Cash Flow | 16 Thousand | - | - | 51.03 Million | -2.01 Million | 50.79 Million |
| Debt repayment | - | - | - | -284 Thousand | -2.66 Million | -141 Thousand |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | 16 Thousand | - | -2.68 Million | 32.46 Million | 390.00 | - |
| Other Financing Activities | 16 Thousand | - | 2.68 Million | 603 Thousand | 743.09 Thousand | -2.83 Million |
| Accounts receivables | -109 Thousand | - | - | - | 177.59 Thousand | -177.59 Thousand |
| Accounts payables | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - |
| Other working capital | -410 Thousand | -373 Thousand | -302 Thousand | -425 Thousand | -234.9 Thousand | -97.37 Thousand |
| Cash at beginning of period | 13.11 Million | 22.06 Million | 44.26 Million | 1.92 Million | 48.72 Million | 2.98 Million |
| Cash at end of period | 9.83 Million | 13.11 Million | 22.06 Million | 22.06 Million | 44.26 Million | 48.72 Million |
| Capital Expenditure | -4000.00 | -2000.00 | -1000.00 | -18 Thousand | -10.13 Thousand | -6867.00 |
| Effect of forex changes on cash | 6000.00 | 278 Thousand | 761 Thousand | 1.14 Million | 1.56 Million | -1.17 Million |
| Net cash flow / Change in cash | -3.28 Million | -8.95 Million | -22.19 Million | 20.14 Million | -4.46 Million | 45.74 Million |
| Free Cash Flow | -5.66 Million | -7.13 Million | -5.43 Million | -14.51 Million | -4 Million | -3.88 Million |
SEAV
CRFQF
NTNX
ISDCF
SDF
STAA